Design and baseline characteristics of a cohort study in Japanese patients with hypercholesterolemia: The Japan Lipid Intervention Trial (J- LIT)

Current Therapeutic Research - Clinical and Experimental

Volumn 61, Issue 4, 2000, Pages 219-243

  Matsuzawa, Yuji ^a   Itakura, Hiroshige ^b   Kita, Toru ^c   Mabuchi, Hiroshi ^d   Matsuzaki, Masunori ^e   Nakaya, Noriaki ^f   Oikawa, Shinichi ^g   Saito, Yasushi ^h   Sasaki, Jun ⁱ   Shimamoto, Kazuaki ^j  

^a OSAKA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

^e YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f Tokyo Metropol Natl H I O H H   (Japan)

^g TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Cholesterol; Cohort study; Coronary heart disease; Hypercholesterolemia; Simvastatin; Triglycerides

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROGENESIS; CLINICAL PROTOCOL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG SAFETY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; JAPAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SECONDARY PREVENTION;

EID: 0034121421     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(00)89037-2     Document Type: Article

References (38)

1. 1. Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 1986;256:2835-2838.
2. 2. Stamler J, Wentworth D, Neaton JD. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256:2823-2828.
3. 3. Keys A, Menotti A, Aravanis C, et al. The Seven Countries Study: 2,289 deaths in 15 years. Prev Med. 1984;2:141-154.
4. 4. Lipid Research Clinical Program. The Lipid Research Clinics Coronary Primary Prevential Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251: 351-364.
5. 5. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-1245.
6. 6. Oliver MF, Heady JA, Morris JN, et al. A cooperative trial in the primary prevention of ischaemic heart disease using clofibrate. Reports from the committee of principal investigators. Br Heart J. 1978;40;1069-1118.
7. 7. Downs JR. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - results of AFCAPS/TexCAPS. JAMA. 1998;279: 1615-1622.
8. 8. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307.
9. 9. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994,344:1383-1389.
10. 10. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-1009.
11. 11. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
12. 12. Sugimoto K, Chikamori T, Kitaoka H, et al. Efficacy of cholesterol lowering therapy on the prognosis of Japanese patients with coronary heart disease. J Noninvasive Cardiol. 1999;3:86-90.
13. 13. Alberts AW. Discovery, biochemistry and biology of lovastatin. Am J Cardiol. 1988;62: 10J-15J.
14. 14. Tarui S. Background and complications of Japanese hyperlipidemic patients [in Japanese]. Jpn J Atheroscler. 1990;18:1-16.
15. 15. Shimamoto T, Komachi Y, Inada H, et al. Trends for coronary heart disease and stroke and their risk factors in Japan. Circulation. 1989;79:503-515.
16. 16. Okayama A, Ueshima H, Marmot MG, et al. Changes in total serum cholesterol and other risk factors for cardiovascular disease in Japan 1980-1989. Int J Epidemiol. 1993;22: 1038-1047.
17. 17. Chikamori T, Takahashi T, Sugimoto K, et al. Clinical significance of the assessment of dyslipidemia in relation to other coronary risk factors in identifying high-risk patients with coronary artery disease in Japan. J Noninvasive Cardiol. 1997;1:33-37.
18. 18. Shimamoto T, Iso H, Iida M, et al. Epidemiology of cerebrovascular disease: Stroke epidemic in Japan. J Epidemiol. 1996;6(Suppl 3):S43-S47.
19. 19. Brandi ML. Natural and synthetic isoflavones in the prevention and treatment of chronic disease. Calcif Tissue Int. 1997;61(Suppl):S5-S8.
20. 20. Iso H, Sato S, Folsom AR, et al. Serum fatty acids and fish intake in rural Japanese, urban Japanese, Japanese American and Caucasian American men. Int J Epidemiol. 1989;18:374-381.
21. 21. Telecom Health Research Group. Cardiovascular risk factors among Japanese and American telephone executives. Int J Epidemiol. 1977;6:7-15.
22. 22. Hubert HB, Feinleib M, McNamara PM, et al. Obesity and an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67:968-977.
23. 23. Sakata K, Labarthe DR. Changes in cardiovascular disease risk factors in three Japanese national surveys, 1971-1990. J Epidemiol. 1996;6:93-107.
24. 24. Omae T. Changing pattern of cardiovascular disease in the Japanese population in relation to hypertension control programs. J Cardiovasc Pharmacol. 1990;16(Suppl 7):S81-S82.
25. 25. Health and Welfare Statistics Association. Annual statistical report of national health condition. 2-2 Vital statistics [in Japanese]. J Health Welfare Stat. 1998;45:43-75.
26. 26. Investigating Committee on Guidelines for Diagnosis and Treatment of Hyperlipidemias, Japan Atherosclerosis Society. Guidelines for diagnosis and treatment of hyperlipidemias in adults. Jpn J Atheroscler. 1997;25:1-34.
27. 27. Health and Welfare Statistics Association. Annual statistical report of national health condition. 2-2 Vital statistics [in Japanese]. J Health Welfare Stat. 1991;38:43-75.
28. 28. International Statistical Classification of Diseases, 10th Revision. World Health Organization, 1992.
29. 29. WHO MONICA Project. MONICA Manual, revised edition. Geneva: Cardiovascular Disease Unit, WHO, 1990.
30. 30. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem. 1972; 18:499-502.
31. 31. Kodama K, Sasaki H, Shimizu Y. Trend of coronary heart disease and its relationship to risk factors in a Japanese population: A 26-year follow-up, Hiroshima/Nagasaki study. Jpn Circ J. 1990;54:414-421.
32. 32. Jacobs D, Blackburn H, Higgins M, et al. Report of the Conference on Low Blood Cholesterol: Mortality associations. Circulation. 1992;86:1046-1060.
33. 33. Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement therapy on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991;325:1196-1204.
34. 34. Garrison RJ, Kannel WE, Feinleib M, et al. Cigarette smoking and HDL cholesterol: The Framingham Offspring Study. Atherosclerosis. 1978;30;17-25.
35. 35. Patsch JR. Triglyceride-rich lipoproteins and atherosclerosis. Atherosclerosis. 1994; 110(Suppl):S23-S26.
36. 36. Davis CE, Gordon D, LaRosa J, et al. Correlations of plasma high-density lipoprotein cholesterol levels with other plasma lipid and lipoprotein concentrations. Circulation. 1980;62:IV24-IV30.
37. 37. Curb JD, Reed DM, Yano K, et al. Plasma lipids and lipoproteins in elderly Japanese-American men. J Am Geriatr Soc. 1986;34:773-780.
38. 38. Ministry of Health and Welfare. Cross-sectional survey of diabetes mellitus (a brief report isued on March 18, 1998) [in Japanese]. J Jpn Diabetes Soc. 1998;41:325-331.